

Attorney Docket No. 25352-0022

PATENTS

RECEIVED

JUL 31 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the US Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington DC 20231, on July 23, 2002.

Derek P. Freyberg, Reg. No. 29,250

7/23/02  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hugo O. Villar, et al. : Confirmation No.: 2049

App. No.: 10/082,801 : Art Unit: 1645

Filed: February 22, 2002 : Examiner: Not yet Known

For: ACRIDINES AS STIMULATORS FOR FAS-MEDIATED APOPTOSIS

Commissioner for Patents  
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT


Applicant directs the attention of the Office to the documents listed on the attached Form PTO-1449 substitute (1 sheet), which may be relevant to the examination of this application.

This application claims the benefit under 35 USC 119(e) of Application No. 60/274,535, filed March 8, 2001.

The Examiner is requested to initial and return a copy of each of these forms with future communications relating to this application.

No representation is made by this Information Disclosure Statement that a search has been made; or that the information disclosed is, or is considered to be, material to patentability under 37 CFR 1.56(b).

Respectfully submitted,



Derek P. Freyberg  
Attorney for Applicant  
Reg. No. 29,250

RECEIVED  
JUL 31 2002  
TECH CENTER 1600/2900

Customer No.: 25213

Heller Ehrman White & McAuliffe  
275 Middlefield Road  
Menlo Park, California 94025-3506  
(650) 324-7014  
July 23, 2002

370140 v01.SV (7x1\_01!.DOC)  
07/23/02 2:51 PM0

<b>INFORMATION DISCLOSURE STATEMENT</b> <small>(37 CFR 1.56, 1.97, and 1.98)</small>  SHEET 1 OF 1				ATTORNEY DOCKET 25352-0022		APPLICATION NO. 10/082,801	
				APPLICANT(S)  Hugo O. Villar, et al.			
				FILING DATE February 8, 2002		GROUP 1645	

OFFICE  
JUL 26 2002  
PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS						
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	NAME	CLASS/ SUBCLASS	FILING DATE (If appropriate)
	1	3,710,795	01/1973	Higuchi et al	128/260	
	2	5,294,715	03/1994	Papadopoulou-Rosenzweig et al.	546/106	
	3	5,567,317	10/1996	Kauvar	210/635	
	4	5,587,293	12/1996	Kauvar et al.	435/7.21	

FOREIGN PATENT DOCUMENTS					
† EX'R INITIAL	* REF. #	PATENT NUMBER	DATE (MO/YR)	COUNTRY	TRANSLATION (YES/NO)
	5	1 - 221364	09/1989	Japan	English abstract only
	6	0 446 604 A2	09/1991	EP	
	7	95/02397	01/1995	PCT	
	8	96/39818	12/1996	PCT	
	9	44 44 045	6/1996	DE	equivalent to #11
	10	2,164,766	6/1996	CA	
	11	97/27179	07/1997	PCT	
	12	98/54148	12/1998	PCT	
	13	99/58126	11/1999	PCT	
	14	99/64054	12/1999	PCT	
	15	00/32175	06/2000	PCT	
	16	00/32175	06/2000	PCT	

RECEIVED  
JUL 31 2002  
TECH CENTER 1600/2900

OTHER DOCUMENTS	
† EX'R INITIAL	* REF. #
	17
	18

CITATION (Author, Article Title, Journal/Book Title, Date, Pertinent Pages, etc.)  Houghton, "Apoptosis and drug response", <i>Current Opinion in Oncology</i> , 1999, 11:475-481.  Siegel et al., "The Role of Fas and related death receptors in autoimmune and other disease states", <i>J Allergy Clin Immunol</i> , vol. 102, no. 5, part 1, May 1999.	EXAMINER'S SIGNATURE    DATE CONSIDERED
---	---

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. *Include copy of this form in next communication to applicant.*  
 \* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).